{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T08:31:59Z","timestamp":1793694719167,"version":"4.5.1"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s40265-026-02290-5","type":"journal-article","created":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T02:20:31Z","timestamp":1772763631000},"page":"573-579","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Becotatug Vedotin: First Approval"],"prefix":"10.1007","volume":"86","author":[{"given":"Hannah A.","family":"Blair","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,6]]},"reference":[{"key":"2290_CR1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.697369","volume":"11","author":"X Chen","year":"2021","unstructured":"Chen X, Liang R, Lai L, et al. Prognostic role of EGFR\/p-EGFR in patients with nasopharyngeal carcinoma: a meta-analysis. Front Oncol. 2021;11:697369.","journal-title":"Front Oncol"},{"issue":"5","key":"2290_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/cells10051206","volume":"10","author":"EA Karlsen","year":"2021","unstructured":"Karlsen EA, Kahler S, Tefay J, et al. Epidermal growth factor receptor expression and resistance patterns to targeted therapy in non-small cell lung cancer: a review. Cells. 2021;10(5):1206.","journal-title":"Cells"},{"issue":"3","key":"2290_CR3","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1038\/sj.bjc.6603566","volume":"96","author":"CW Reuter","year":"2007","unstructured":"Reuter CW, Morgan MA, Eckardt A. Targeting EGF-receptor-signalling in squamous cell carcinomas of the head and neck. Br J Cancer. 2007;96(3):408\u201316.","journal-title":"Br J Cancer"},{"key":"2290_CR4","unstructured":"Lepu Biopharma. Inside information announcement marketing approval obtained in China for Meiyouheng (becotatug vedotin injection) [media release]. 30 Oct 2025. http:\/\/www.lepubiopharma.com."},{"key":"2290_CR5","unstructured":"Lepu Biotechnology Co. Ltd. Becotatug vedotin for injection: Chinese prescribing information. Accessed 16 Dec 2025."},{"key":"2290_CR6","unstructured":"Lepu Biopharma. Fast Track Designation granted by the FDA to MRG003 for the treatment of recurrent\/metastatic nasopharyngeal carcinoma (R\/M NPC) [media release]. 4 Dec 2023. http:\/\/www.lepubiopharma.com."},{"key":"2290_CR7","unstructured":"Lepu Biopharma. Breakthrough Therapy Designation granted by the FDA to MRG003 for the treatment of R\/M NPC [media release]. 5 Aug 2024. http:\/\/www.lepubiopharma.com."},{"key":"2290_CR8","unstructured":"Lepu Biopharma. Lepu Biopharma seeks IPO in Hong Kong, and more - daily news [media release]. 1 Nov 2021. http:\/\/www.lepubiopharma.com."},{"issue":"7","key":"2290_CR9","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1001\/jamaoncol.2022.0503","volume":"8","author":"MZ Qiu","year":"2022","unstructured":"Qiu MZ, Zhang Y, Guo Y, et al. Evaluation of safety of treatment with anti-epidermal growth factor receptor antibody drug conjugate MRG003 in patients with advanced solid tumors: a phase 1 nonrandomized clinical trial. JAMA Oncol. 2022;8(7):1042\u20136.","journal-title":"JAMA Oncol"},{"issue":"Suppl 2","key":"2290_CR10","doi-asserted-by":"publisher","first-page":"S559","DOI":"10.1016\/j.annonc.2023.09.2006","volume":"34","author":"F Han","year":"2023","unstructured":"Han F, Wang F, Shi YR, et al. MRG003: a novel EGFR-targeted antibody-drug conjugant (ADC) for recurrent\/metastatic nasopharyngeal carcinoma [abstract no. 860MO plus presentation]. Ann Oncol. 2023;34(Suppl 2):S559.","journal-title":"Ann Oncol"},{"key":"2290_CR11","doi-asserted-by":"crossref","unstructured":"Han F, Wang X, Xiang Y, et al. Becotatug vedotin vs. chemotherapy in pre-heavily treated advanced nasopharyngeal carcinoma: a randomized, controlled, multicenter, open-label study [abstract no. LBA6005]. J Clin Oncol. 2025;43(17 Suppl).","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA6005"},{"key":"2290_CR12","unstructured":"US National Institutes of Health. ClinicalTrials identifier NCT05126719. 2023. https:\/\/clinicaltrials.gov. Accessed 11 Dec 2025."},{"issue":"Suppl 4","key":"2290_CR13","doi-asserted-by":"publisher","first-page":"S1554","DOI":"10.1016\/j.annonc.2024.10.425","volume":"35","author":"RH Xu","year":"2024","unstructured":"Xu RH, Ruan D, Han F, et al. Preliminary results of phase II study to evaluate safety and efficacy of combination pucotenlimab with epidermal growth factor receptor-ADC (EGFR-ADC) MRG003 in recurrent or metastatic nasopharyngeal carcinoma (R\/M-NPC) [abstract no. 402O]. Ann Oncol. 2024;35(Suppl 4):S1554.","journal-title":"Ann Oncol"},{"issue":"Suppl 2","key":"2290_CR14","first-page":"S856","volume":"36","author":"D Ruan","year":"2025","unstructured":"Ruan D, Han F, Zhou Y, et al. Updated long term efficacy results of phase II study for becotatug vedotin combined with pucotenlimab in recurrent or metastatic nasopharyngeal carcinoma (R\/M-NPC) [abstract no. 1390P]. Ann Oncol. 2025;36(Suppl 2):S856.","journal-title":"Ann Oncol"},{"key":"2290_CR15","unstructured":"US National Institutes of Health. ClinicalTrials identifier NCT05688605. 2023. https:\/\/clinicaltrials.gov. Accessed 11 Dec 2025."},{"issue":"Suppl 2","key":"2290_CR16","doi-asserted-by":"publisher","first-page":"S590","DOI":"10.1016\/j.annonc.2023.09.2083","volume":"34","author":"L Xue","year":"2023","unstructured":"Xue L, Han Y, Zhang Q, et al. Efficacy and safety of a novel anti-EGFR ADC MRG003 in recurrent or metastatic squamous cell carcinoma of the head and neck patients [abstract no. 939P plus poster]. Ann Oncol. 2023;34(Suppl 2):S590.","journal-title":"Ann Oncol"},{"issue":"Suppl 2","key":"2290_CR17","first-page":"S855","volume":"36","author":"ZM Li","year":"2025","unstructured":"Li ZM, Zhou Y, Lin J, et al. Preliminary results of phase II study to evaluate safety and efficacy of becotatug vedotin in combination with pucotenlimab as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck (R\/M-SCCHN) [abstract no. 1389P]. Ann Oncol. 2025;36(Suppl 2):S855.","journal-title":"Ann Oncol"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02290-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-026-02290-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02290-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T05:00:59Z","timestamp":1774069259000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-026-02290-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,6]]},"references-count":17,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["2290"],"URL":"https:\/\/doi.org\/10.1007\/s40265-026-02290-5","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,6]]},"assertion":[{"value":"15 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Hannah A. Blair is a salaried employee of Adis International Ltd\/Springer Nature and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of Interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval, Consent to Participate, Consent to Publish, Availability of Data and Material, Code Availability"}}]}}